UC7AI180306

Resources and Workforce Development for Research on NIH/NIAID High Priority Pathogens at the University of Missouri Regional Biocontainment Laboratory - Overall Project Summary

Resources and Workforce Development for Research on NIH/NIAID High Priority Pathogens at the University of Missouri Regional Biocontainment Laboratory

The University of Missouri Regional Biocontainment Laboratory (RBL) was commissioned in 2009 as an $18M, 12,377 NSF BSL-3/ABSL-3 facility. During its thirteen years of operation, the RBL, since named the MU Laboratory for Infectious Disease Research (LIDR), has been a centerpiece of the broader infectious disease research community at the University of Missouri, receiving strong institutional commitment in the recruitment and sustainment of world-class faculty for management of the RBL/LIDR and for conducting research on high priority pathogens.

The LIDR operates shared research resources, including state-of-the-art equipment and professional services in microbiology, aerobiology, immunology, and animal model core facilities that serve the needs of researchers on campus and in the broader regional and national communities. The faculty and professional staff of the LIDR are part of the NIH/NIAID RBL-NBL network, with collaborative interactions that facilitate sharing of best practices and knowledge, providing synergy in achieving our collective biodefense and emerging infectious disease research agenda.

During the COVID pandemic, the MU LIDR, along with its RBL and NBL partners, led the response to the pandemic and are committed to strengthening pandemic preparedness of the nation, by providing BSL-3/ABSL-3 training, professional staff, and research services that allow for rapid responses in all areas, including development of animal models and the evaluation of numerous treatments, disinfectants, and vaccine platforms to combat the pandemic.

The long-term goal of the present application is to sustain a leading effort for development of novel medical countermeasures for combating the ever present and changing threats of emerging and re-emerging infectious diseases, while training an outstanding cadre of next generation scientists and professionals in biocontainment. The goals of the proposed cores in facility management, maintenance and operations, BSL3 practices, and biocontainment research support services are to educate and train the next generation of scientists and biocontainment professionals in biodefense and emerging infectious diseases, and to facilitate and enhance the development of novel approaches for prevention and treatment of infections caused by high consequence pathogens whose natural or deliberate transmission pose a threat to public health and national security.

Towards these goals, the proposed cores will work within the broader infectious disease community at MU and the NIH/NIAID RBL-NBL network for enhancement of research productivity and discovery, and continued sharing of information and best practices in order to meet the changing priorities and needs of NIH/NIAID for biodefense and emerging infectious diseases.

University Of Missouri System

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Columbia, Missouri 652115547 United States

Single Zip Code

Limited Competition: Resources and Workforce Development for the Regional Biocontainment Laboratories (UC7 Clinical Trial Not Allowed) (RFA-AI-22-075)

Amendment Since initial award the total obligations have increased 182% from $2,595,464 to $7,330,232.